 
 
 
19th July 2023 
IOLCP/CGC/2023 
 
National Stock Exchange of India Ltd. 
Exchange Plaza, Plot no. C/1, G Block, 
Bandra-Kurla Complex, Bandra (E) 
Mumbai - 400 051 
BSE Limited 
Phiroze Jeejeebhoy Towers,  
Dalal Street 
Mumbai- 400 001 
Security Symbol: IOLCP 
Security Code: 524164 
 
Sub.: Business Responsibility and Sustainability Report of the Company for the FY 2022-23 
 
Dear Sir, 
 
Pursuant to the provisions of Regulation 34(2) and other applicable provisions of the SEBI (Listing 
Obligations and Disclosure Requirements) Regulations, 2015, read with applicable SEBI Circulars, 
please find attached herewith the Business Responsibility and Sustainability Report (BRSR) of the 
Company for the FY 2022-23, which also forms part of the Annual Report for FY 2022-23. The BRSR 
along with Annual Report for FY 2022-23 is available on the website of the Company at 
https://www.iolcp.com//uploads/IOL-Annual-Report-2022-23.pdf  
 
This is for your information and record please. 
 
Thanking You, 
 
Yours faithfully, 
For IOL Chemicals and Pharmaceuticals Limited 
 
 
 
Abhay Raj Singh 
Vice President & Company Secretary 
 
 
ABHAY 
RAJ 
SINGH
Digitally signed 
by ABHAY RAJ 
SINGH 
Date: 2023.07.19 
15:45:52 +05'30'
Financial Statements
Statutory Reports
Corporate Overview
1
Business Responsibility and Sustainability Report
SECTION A: GENERAL DISCLOSURES
I.	
Details of the listed entity
1
Corporate Identity Number (CIN) of the Listed Entity
L24116PB1986PLC007030
2
Name of the Listed Entity
IOL Chemicals and Pharmaceuticals Limited
3
Year of incorporation
1986
4
Registered office address
Village Fatehgarh Channa, Mansa Road, District Barnala – 148 101, 
Punjab, India
5
Corporate address
85, Industrial Area ‘A’ Ludhiana – 141 003, Punjab, India.
6
E-mail
investor@iolcp.com
7
Telephone
+(91)-(161)-2225531/35
8
Website
www.iolcp.com
9
Financial year for which reporting is being done
April 2022 to March 2023
10
Name of the Stock Exchange(s) where shares are listed
National Stock Exchange of India Limited (NSE)
BSE Limited (BSE)
11
Paid-up Capital
` 58,70,55,020
12
Name and contact details (telephone, e-mail address) of the person 
who may be contacted in case of any queries on the BRSR report
Mr. Abhay Raj Singh
+(91)-(161)-2225531/35
abhayrajsingh@iolcp.com
13
Reporting boundary – Are the disclosures under this report made on a 
standalone basis  (i.e. only for the entity) or on a consolidated basis (i.e. 
for the entity and all the entities which form a part of its consolidated 
financial statements, taken together).
Standalone basis
II.	
Products/services
	
14.	
Details of business activities (accounting for 90% of the turnover):
Sr. 
No.
Description of Main Activity
Description of  Business Activity
% of Turnover of the entity
1.
Manufacturing
Chemical Segment
51%
2.
Manufacturing
Pharma Segment
49%
	
15.	
Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
Sr. 
No.
Product/Service
NIC Code
% of total Turnover contributed
1
Ethyl Acetate
20119
39.34%
2
Ibuprofen
21002
34.51%
3
Non Ibuprofen APIs
21002
22.25%
4
Other
20119 / 21002
 3.90%
Total
100%
III.	 Operations
	
16.	 Number of locations where plants and/or operations/offices of the entity are situated:
Location
Number of plants
Number of offices
Total
National
1
3
4
International
-
-
-
	
17.	
Markets served by the entity:
	
	
a)	
Number of locations
Locations
Number
National (No. of States)
4
International (No. of Countries)
-
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
2
	
	
b)	
What is the contribution of exports as a percentage of the total turnover of the entity?
	
	
	
25%
	
	
c)	
A brief on types of customers
	
	
	
1.	
Specialty Chemicals/Products Manufacturing Companies
	
	
	
2.	
Pharmaceuticals Finished Dosage Manufacturing Companies
IV.	
Employees
	
18.	 Details as at the end of Financial Year:
	
	
a)	
Employees and workers (including differently abled):
Sr.
No.
Particulars
Total
(A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
EMPLOYEES
1.
Permanent (D)
2569
2494
97.08%
75
2.92%
2.
Other than Permanent (E)
140
127
90.71%
13
9.29%
3.
Total employees (D + E)
2709
2621
96.75%
88
3.25%
WORKERS
4.
Permanent (F)
0
0
0
0
0
5.
Other than Permanent (G)
0
0
0
0
0
6.
Total workers (F + G)
0
0
0
0
0
	
	
b)	
Differently abled Employees and workers:
Sr.
No.
Particulars
Total
(A)
Male
Female
No. (B)
% (B / A)
No. (C)
% (C / A)
DIFFERENTLY ABLED EMPLOYEES
1.
Permanent (D)
0
0
0
0
0
2.
Other than Permanent (E)
0
0
0
0
0
3.
Total differently abled employees  
(D + E)
0
0
0
0
0
DIFFERENTLY ABLED WORKERS
4.
Permanent (F)
0
0
0
0
0
5.
Other than permanent (G)
0
0
0
0
0
6.
Total differently abled workers
(F + G)
0
0
0
0
0
	
19.	
Participation/ Inclusion/ Representation of women
Total
(A)
No. and percentage of Females
No. (B)
% (B / A)
Board of Directors
8
1
12.5%
Key	Management Personnel
2
0
0.00%
	
20.	 Turnover rate for permanent employees and workers
	
	
(Disclose trends for the past 3 years)
FY 2022-23
(Turnover rate in current FY)
FY 2021-22  
(Turnover rate in previous FY)
FY 2020-21 (Turnover rate in  
the year prior to the previous FY)
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent Employees
97%
3%
100%
97%
3%
100%
97%
3%
100%
Permanent Workers
0
0
0
0
0
0
0
0
0
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
3
V.	
Holding, Subsidiary and Associate Companies (including joint ventures)
	
21.	
(a)	
Names of holding/ subsidiary/ associate companies/ joint ventures
Sr.  
No.
Name of the holding/ subsidiary/  
associate companies/ joint ventures (A)
Indicate whether holding/ 
Subsidiary/ Associate/ Joint 
Venture
% of shares held 
by listed entity
Does the entity indicated at column A, 
participate in the Business Responsibility 
initiatives of the listed entity? (Yes/No)
1
IOL Life Sciences Limited
Wholly-owned Subsidiary
100%
No
2
IOL Specialty Chemicals Limited
Wholly-owned Subsidiary
100%
No
3
IOL Global Limited
Wholly-owned Subsidiary
100%
No
4
IOL-Foundation
Wholly-owned Subsidiary
100%
No
VI.	 CSR Details
	
22.	 (i)	
Whether CSR is applicable as per Section  135 of Companies Act, 2013: (Yes/No): Yes
	
	
(ii)	
Turnover (in `)	
22,17,11,04,207
	
	
(iii)	 Net worth (in `)	
15,06,54,92,723
VII.	 Transparency and Disclosures Compliances
	
23.	 Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible 
Business Conduct:
Stakeholder 
group from whom 
complaint is received
Grievance Redressal 
Mechanism in Place (Yes/No)
(If Yes, then provide web-link for 
grievance redress policy)
FY 2022-23
Current Financial Year
FY 2021-22
Previous Financial Year
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the year
Remarks
Communities
Yes 
https://www.iolcp.com/
investors/services
Nil
Nil
Nil
Nil
Investors (other	
than shareholders)
Nil
Nil
Nil
Nil
Shareholders
Yes
https://www.iolcp.com/
investors/services
1
Nil
Nil
Nil
Employees and 
workers
Yes
https://www.iolcp.com/
about-us/policies
Nil
Nil
Nil
Nil
Customers
Nil
Nil
Nil
Nil
Value Chain Partners
Nil
Nil
Nil
Nil
Other  
(please specify)
Nil
Nil
Nil
Nil
	
24.	 Overview of the entity’s material responsible business conduct issues
	
	
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 
matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt or 
mitigate the risk along-with its financial implications, as per the following format
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
4
	
	
As a pharmaceuticals and Specialty Chemical firm, we have identified, evaluated, and reported on certain key issues. In 
FY 2020-21, we completed a materiality evaluation based on peer review across environmental, social and governance 
dimensions. The evaluation process has provided us with great insights into topics that are important to us, our operations, 
as well as how they might impact our future.
Sr.  
No.
Material issue identified
Indicate 
whether risk 
or opportunity 
(R/O)
Rationale for  identifying the risk/ 
opportunity
In case of  risk,  
approach to  adapt  
or   mitigate
Financial implications of 
the risk or opportunity 
(Indicate positive or 
negative implications)
1.
Manufacturing of API and 
specialty chemicals – Effluent 
generation from process 
having potential of water 
pollution and soil pollution
O
Zero liquid Discharge process is 
implemented to treat, recycle and 
reuse the good quality water in 
cooling towers hence conserve 
fresh water
N.A.
Positive
2.
Health & Safety
R
In chemical and API industry, 
Health & Safety can directly 
impact people and community 
and disrupt the operations
Environment, Health 
& Safety
Management Plan,
Negative
3.
Employee Development
O
Learning and development 
opportunities for various level of 
employees
N.A.
Positive
4.
Regulatory Issues and 
Compliance
R
Non-compliance may impact the 
brand image and customer trust 
and engagement
Adherence to 
compliance
monitoring system
Negative
5.
Energy Efficiency
O
Minimise the greenhouse gas 
(GHG) emissions, improve 
resource efficiency, cost saving, 
cleaner environment etc.
N.A.
Positive
6.
Reduction in Carbon  
Footprint
O
Mitigation of impacts of Climate 
change and ensure long-term 
sustainable business
N.A.
Positive
SECTION B: MANAGEMENT AND PROCESS DISCLOSURES
This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the 
NGRBC Principles and Core Elements.
Disclosure Questions
P
1
P
2
P
3
P
4
P
5
P
6
P
7
P
8
P
9
Policy and management processes
1.	
a)	 Whether your entity’s policy/policies cover each principle and its 
core elements of the NGRBCs. (Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
	
b) 	 Has the policy been approved by the Board? (Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
	
c) 	 Web-link of the Policies, if available
https://www.iolcp.com/investors/corporate-policies
2.	
Whether the entity has translated the policy into procedures.  
(Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
3.	
Do the enlisted policies extend to your value chain partners? (Yes/No)
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
4.	
Name of the national and international codes/ certifications/ labels/  
standards (e.g. Forest Stewardship Council, Fairtrade, Rainforest 
Alliance, Trustea) standards (e.g. SA 8000, OHSAS, ISO, BIS) adopted 
by your entity and mapped to each principle.
SA 8000:2014, ISO 14001:2015, ISO 50001:2018
ISO 450012018, ISO 9001:2015, GMP Certificate
EUGMP Certificate by OGYÉI, EP Certificates from EDQM, DUNS Number 
Certificate, Kosher Certificate, Drug Manufacturing License 1689-OSP,
Free Sale Certificate
5.	
Specific commitments, goals and targets set by the entity with 
defined timelines, if any.
Please refer details provided in the Annual Report and ‘Sustainability Report 
for FY 2022-23.
6.	
Performance of the entity against the specific commitments, goals 
and targets along-with reasons in case the same are not met.
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
5
Disclosure Questions
P
1
P
2
P
3
P
4
P
5
P
6
P
7
P
8
P
9
Governance, leadership and oversight
7.	
Statement by director responsible for the business responsibility 
report, highlighting ESG related challenges, targets and 
achievements (listed entity has flexibility regarding the placement of 
this disclosure)
We are resolute in our commitment to incorporating sustainability 
principles across our value chain even while we broaden the scope of 
our positive social impacts and penetrate new markets. Our goal is to 
provide our patients and customers with high-quality, cost-effective goods 
that may save and improve their lives while also attaining a high growth 
trajectory in terms of expanding our business. We’ll keep working towards 
improving and accomplishing our targets while delivering our stakeholders 
with effective solutions. In our pursuit of sustainability, we look forward 
to encouragement and support from all stakeholders for greener and 
sustainable future.
8.	
Details of the highest authority responsible for implementation and 
oversight of the Business Responsibility policy(ies).
Mr. Varinder Gupta, Managing Director
DIN: OOO44068
9.	
Does the entity have a specified Committee of the Board/Director 
responsible for decision-making on sustainability related issues?  
(Yes/No). If yes, provide details.
Corporate Social Responsibility Committee (CSR Committee). The 
composition of the CSR Committee is as follows:
Mr. Varinder Gupta, Chairman (DIN: 00044068)
Mr. Vikas Gupta, Member (DIN: 07198109)
Dr. Sandhya Mehta, Member (DIN: 06954964)
10.	 Details of Review of NGRBCs by the Company:
	
Subject for Review
Indicate whether review was 
undertaken by Director/ Committee of 
the Board/ Any other Committee
Frequency (Annually (A)/ Half yearly 
HF/ Quarterly Q/ Any other AO– please 
specify)
P
1
P
2
P
3
P
4
P
5
P
6
P
7
P
8
P
9
P
1
P
2
P
3
P
4
P
5
P
6
P
7
P
8
P
9
	
Performance against above policies and follow up action
Yes Yes Yes Yes Yes Yes Yes Yes Yes A
A
A
A
A
A
A
Q
A
	
Compliance with statutory requirements of relevance to the 
principles, and, rectification of any non-compliances
Yes Yes Yes Yes Yes Yes Yes Yes Yes A
A
A
A
A
A
A
Q
A
11.	 Has the entity carried out independent assessment/evaluation of the 
working of its policies by an external agency? (Yes/No). If yes, provide 
name of the agency.
P  
1
P
2
P 
3
P 
4
P 
5
P 
6
P 
7
P 
8
P
 9
No
No
No
No
No
Yes*
No
No
No
*British Standards Institution (BSI)
12.	
If answer to question (1) above is “No” i.e. not all Principles are covered by a policy, reasons to be stated:
Questions
P 1
P 2
P 3
P 4
P 5
P 6
P 7
P 8
P 9
The entity does not consider the Principles material to its business (Yes/No)
Not Applicable since the policies of the  
Company cover all Principles on NGRBCs
The entity is not at a stage where it is in a position to formulate and 
implement the policies on specified principles (Yes/No)
The entity does not have the financial or/human and technical resources 
available for the task (Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
SECTION C: PRINCIPLE WISE PERFORMANCE DISCLOSURE
This section is aimed at helping entities demonstrate their performance in integrating the Principles and Core Elements with key 
processes and decisions. The information sought is categorised as “Essential” and “Leadership”. While the essential indicators are 
expected to be disclosed by every entity that is mandated to file this report, the leadership indicators may be voluntarily disclosed by 
entities which aspire to progress to a higher level in their quest to be socially, environmentally and ethically responsible.
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
6
PRINCIPLE 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, 
Transparent and Accountable
Essential Indicators
1.	
Percentage coverage by training and awareness programs on any of the Principles during the financial year:
	
There are regular training sessions for new inductees.
Segment
Total number of training 
and awareness programs 
held
Topics/principles covered under the training 
and its impact
Percentage of persons in 
respective category covered by 
the awareness programs
Board of Directors
2 - POSH; - IOL Code of Conduct
100
Key Managerial Personnel
2 - POSH; - IOL Code of Conduct
100
Employees other than BoD and KMPs
69 - Social Accountability; - Data Integrity
- POSH; - IOL Code of Conduct
42.51
2.	
Details of fines/ penalties/ punishment/ award/ compounding fees/ settlement amount paid in proceedings (by 
the entity or by directors/ KMPs) with regulators/ law enforcement agencies/ judicial institutions, in the financial 
year. (Note: the entity shall make disclosures on the basis of materiality as specified in Regulation 30 of the Listing 
Regulations, 2015 and as disclosed on the entity’s website):
	
For FY23, there were no cases pending pertaining to unfair trade practices, irresponsible advertising and/or anti-competitive 
behavior. Additionally, there were no cases of corruption, with reference to the employees or the business partners.
3.	
Of the instances disclosed in Question 2 above, details of the Appeal/Revision preferred in cases where monetary or 
non-monetary action has been appealed:
	
Not Applicable
4.	
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide 
a web-link to the policy:
	
Yes, Organisation has implemented anti-corruption and anti-bribery policy, for policy detail refer. https://www.iolcp.com/
investors/corporate-policies
5.	
Number of Directors/ KMPs/ employees/ workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/corruption:
	
No Directors/ KMPs/ employees/ workers were involved in bribery/corruption in the Financial Year 2022-23.
6.	
Details of complaints with regard to conflict of interest:
	
No complaint was received with regard to conflict of interest against Directors/KMPs in the Financial Year 2022-23.
7.	
Provide details of any corrective action taken or underway on issues related to fines/ penalties/ action taken by 
regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest:
	
Not applicable
Leadership Indicators
1.	
Awareness programs conducted for value chain partners on any of the Principles during the financial year:
Total number of awareness 
programs held
Topics/principles covered  
under the training
%age of value chain partners covered (by value of business  
done with such partners) under the awareness programs
06
- Code of Conduct 
- SA8000 awareness
- Transportation Safety guidelines
- Sustainable Procurement Policy.
- NDMA Impurity Declaration
- EHS&S Awareness
80% (100% of Key Material Supplier)
2.	
Does the entity have processes in place to avoid/ manage conflict of interests involving members of the Board? (Yes/
No) If Yes, provide details of the same.
	
Yes, every Director of the Company discloses his/her concern or interest in the Company or companies or bodies corporate or firms 
or other association of individuals and any change therein, annually or upon any change, which also includes the shareholding. 
These disclosures are shared with the Finance department which flags off the parties in their system for monitoring and tracking 
transaction(s) entered by the Company with such parties.
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
7
	
Further, a declaration is also taken annually from the Directors under the Code of Conduct confirming that they will always act in 
the interest of the Company and ensure that any other business or personal association which they may have, does not involve 
any conflict of interest with the operations of the Company and their role therein. The Senior Management also affirms annually 
that they have not entered into any material, financial and commercial transactions, which may have a potential conflict with the 
interest of the Company at large.
PRINCIPLE 2: Businesses should provide goods and services in a manner that is sustainable and safe
Essential Indicators
1.	
Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the 
environmental and social impacts of product and processes to total R&D and capex investments made by the entity, 
respectively.
Financial Year 2022-23 (%)
Financial Year 2021-22 (%) 
Details of improvements in environmental and  
social impacts
R&D
60%
40% All R&D Investments are focussed on sustainable 
technologies, Backward Integration, enhancing process 
efficiency and product quality.
Capex
10.14%
2.28%
2.	
a)	
Does the entity have procedures in place for sustainable sourcing? (Yes/No): Yes
	
b)	
If yes, what percentage of inputs were sourced sustainably? 100% for Key Raw Material Suppliers
3.	
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, 
for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
	
Plastic waste is disposed off to authorised recyclers in line with requirement of Plastic waste management rules 2016.
	
E-waste is disposed off to Authorised vendor approved by PCB in line with requirements of E-waste rules
	
Specific area is defined for the storage of Hazardous waste within the organisation (Hazard Waste Room)
	
Agreements with GGEPIL, Nimbua Ramky and Re Sustainability are signed for the safe disposal and treatment of the waste to 
complete the proper End of Life Cycle.
	
Authorization Number of IOLCP : HWM/FRESH/BAR/2022/19594048
	
Categories of Hazardous Waste of IOL Chemicals and Pharmaceuticals Limited:
	
1.	
(5.1) Mobile Oil
	
2.	
(5.2) Waste Residue containing oil
	
3.	
(20.3) Distillation Residue
	
4.	
(28.1) Process Residue
	
5.	
(28.2) Spent Catalyst
	
6.	
(28.3) Spent Carbon
	
7.	
(28.4) Off Specification
	
8.	
(28.5) Date expired Products
	
9.	
(33.1) Empty Barrels
	
10.	
(33.2) Contaminated cotton Rags
	
11.	
(35.3) ETP Sludge
	
12.	
(36.2 Spent Carbon
	
13.	
(37.1) sludge from Wet Scrubber
	
14.	
(37.2) Ash from incinerator
	
15.	
(37.3) Concentration & evaporation Residue
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
8
4.	
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes/No).
	
Yes
	
If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to 
Pollution Control Boards?
	
Yes
	
If not, provide steps taken to address the same.
	
N.A.
Leadership Indicators
1.	
Has the entity conducted Life Cycle Perspective/Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? If yes, provide details in the following format?
NIC Code
Name of Product /
Service
% of total Turnover 
contributed
Boundary for which the Life Cycle 
Perspective/Assessment was 
conducted
Whether conducted by 
independent external 
agency (Yes/No)
Results communicated in 
public domain (Yes/No)
If yes, provide the web-link.
21102
Ibuprofen
31%
Cradle to gate emissions
Yes
No
21102
Metformin
8%
Cradle to gate emissions
Yes
No
2.	
If there are any significant social or environmental concerns and/or risks arising from production or disposal of your 
products/services, as identified in the Life Cycle Perspective/Assessments (LCA) or through any other means, briefly 
describe the same along-with action taken to mitigate the same.
Name of Product/Service
Description of the risk/concern
Action Taken
Manufacturing of API and 
specialty chemicals
Effluent generation from process having 
potential of water pollution and soil pollution
Zero liquid Discharge process is implemented to treat, recycle 
and reuse the good quality water in cooling towers
3.	
Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing 
industry) or providing services (for service industry).
Indicate input material
Recycled or re-used input material to total material
FY 2022-23
FY 2021-22
0
0
4.	
Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and 
safely disposed, as per the following format:
FY 2022-23
FY 2021-22
Re-Used
Recycled
Safely Disposed
Re-Used
Recycled
Safely Disposed
Plastics (including packaging)
-
24.359 MT
-
-
18.050 MT
-
E-waste
-
0.520 MT
-
-
0.430 MT
-
Hazardous waste
-
NIL
-
-
NIL
-
Other waste
-
NIL
-
-
NIL
-
5.	
Reclaimed products and their packaging materials (as percentage of products sold) for each product category
Indicate product category
Reclaimed products and their packaging materials as % of total products sold in 
respective category
NIL
NIL
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
9
PRINCIPLE 3: Businesses should respect and promote the well-being of all employees, including those in their value 
chains
Essential Indicators
1.	
a)	
Details of measures for the well-being of employees:
Category
% of employees covered by
Total (A)
Health insurance
Accident insurance
Maternity benefits
Paternity Benefits
Day Care facilities
Number (B)
% (B / A) Number (C)
% (C / A) Number (D)
% (D / A) Number (E)
% (E / A) Number (F)
% (F / A)
Permanent employees
Male
2494
2494
100%
2494
100%
0
0
2494
100%
0
0
Female
75
75
100%
75
100%
75
100%
0
0
75
100%
Total
2569
2569
100%
2569
100%
75
100%
2494
100%
75
100%
Other than Permanent employees
Male
0
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
0
Other
0
0
0
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
0
0
0
0
0
0
	
b)	
Details of measures for the well-being of workers:
Category
% of employees covered by
Total (A)
Health insurance
Accident insurance
Maternity benefits
Paternity Benefits
Day Care facilities
Number (B)
% (B / A) Number (C)
% (C / A) Number (D)
% (D / A) Number (E)
% (E / A) Number (F)
% (F / A)
Permanent employees
Male
0
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
0
Other
0
0
0
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
0
0
0
0
0
0
Other than Permanent employees
Male
0
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
0
Other
0
0
0
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
0
0
0
0
0
0
2.	
Details of retirement benefits, for Current FY and Previous Financial Year
Benefits
FY 2022-23
FY 2021-22
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as a % of 
total workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
No. of employees 
covered as a % of 
total employees
No. of workers 
covered as a % of 
total workers
Deducted and 
deposited with 
the authority 
(Y/N/N.A.)
PF
100%
0 %
Y
100%
0%
Y
Gratuity
100%
0 %
Y
100%
0%
Y
ESI
100%
0 %
Y
100%
0%
Y
Others – please specify 
Pension, Leave incashment Due 
Bonus, Other benefits as per 
policy
100%
0 %
Y
100%
0%
Y
Momento, Cash reward as per 
policy, 10-15 year service  
1 month fix CTC, 15 above  
2 month fixed CTC, farewell 
Party
100%
0%
Y
100 %
0%
Y
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
10
3.	
Accessibility of workplaces
	
Are the premises/offices of the entity accessible to differently abled employees and workers, as per the 
requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by the 
entity in this regard.
	
Yes
4.	
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, 
provide a web-link to the policy.
	
Yes
5.	
Return to work and Retention rates of permanent employees and workers that took parental leave.
Gender
Permanent employees
Permanent workers
Return to work rate
Retention rate
Return to work rate
Retention rate
Male
100%
100%
100%
100%
Female
100%
100%
100%
100%
Total
100%
100%
100%
100%
6.	
Is there a mechanism available to receive and redress grievances for the following categories of employees and 
worker? If yes, give details of the mechanism in brief.
Particulars
Yes/No (If Yes, then give details of the mechanism in brief)
Permanent Workers
Yes (Grievance Redressal System Implemented at Site )
Other than Permanent Workers
Yes
Permanent Employees
Yes
Other than Permanent Employees
Yes
7.	
Membership of employees and worker in association(s) or Unions recognised by the listed entity:
Category
FY 2022-23
FY 2021-22
Total employees/
workers in 
respective 
category (A)
No. of employees/ 
workers in respective 
category, who are part of 
association(s) or Union (B)
% (B / A)
Total employees/
workers in 
respective 
category (C)
No. of employees / 
workers in respective 
category, who are part of 
association(s) or Union (D)
% (D / C)
Total Permanent Employees
- Male
2494
0
0
2494
0
0
- Female
75
0
0
75
0
0
Total Permanent Workers
0
0
0
0
- Male
0
0
0
0
0
0
- Female
0
0
0
0
0
0
8.	
Details of training given to employees and workers:
Category
FY 2022-23
FY 2021-22
Total (A)
On Health and safety 
measures
On Skill upgradation
Total (D)
On Health and safety 
measures
On Skill upgradation
No. (B)
% (B / A)
No. (C)
% (C / A)
No. (E)
% (E / D)
No. (F)
% (F / D)
Employees
Male
2132
1845
86.54%
1855
87.01
2083
1537
73.79%
1557
74.75%
Female
49
36
73.47%
38
77.55
44
27
61.36%
27
61.36%
Total
2181
1881
86.24%
1893
86.80
2127
1564
73.53%
1584
74.47%
Workers
Male
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
Total
0
0
0
0
0
0
0
0
0
0
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
11
9.	
Details of performance and career development reviews of employees and worker:
Category
FY 2022-23
FY 2021-22
Total (A)
No. (B)
% (B / A)
Total (C)
No. (D)
% (D / C)
Employees
Male
2494
2494
100%
2282
2282
100%
Female
75
75
100%
58
58
100%
Total
2569
2569
100%
2340
2340
100%
Workers
Male
0
0
0
0
0
0
Female
0
0
0
0
0
0
Total
0
0
0
0
0
0
10.	 Health and safety management system:
	
a)	
Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). 
If yes, the coverage such system?
	
	
Yes, ISO 45001:2018 certified company and have well established safety management system
	
b)	
What are the processes used to identify work-related hazards and assess risks on a routine and non-routine 
basis by the entity?
	
	
Well Defined Standard Operating procedures are in place for risk assessment - HIRA, AIA, HAZOP
	
c)	
Whether you have processes for workers to report the work related hazards and to remove themselves from 
such risks. (Y/N)
	
	
Yes
	
d)	
Do the employees/worker of the entity have access to non-occupational medical and healthcare services?  
(Yes/ No)
	
	
Yes
11.	 Details of safety related incidents, in the following format:
Safety Incident/Number
Category
FY 2022-23
FY 2021-22
Lost Time Injury Frequency Rate (LTIFR) (per one million-person hours worked)
Employees
0.64
0.84
Workers
0
0
Total recordable work-related injuries
Employees
0
0
Workers
0
0
No. of fatalities
Employees
0
0
Workers
0
0
High consequence work-related injury or ill-health (excluding fatalities)
Employees
0
0
Workers
0
0
12.	 Describe the measures taken by the entity to ensure a safe and healthy work place.
	
Organisation is ISO 45001:2018, Certified Safety management system is implemented at site
13.	 Number of Complaints on the following made by employees and workers:
FY 2022-23
FY 2021-22
Filed during the 
year
Pending resolution 
at the end of year
Remarks
Filed during the 
year
Pending resolution 
at the end of year
Remarks
Working Conditions
0
0
0
0
0
0
Health & Safety
0
0
0
0
0
0
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
12
14.	 Assessments for the year:
Particulars
% of your plants and offices that were assessed  
(by entity or statutory authorities orthird parties)
Health and safety practices
100%
Working Conditions
100%
15.	 Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on 
significant risks/concerns arising from assessments of health & safety practices and working conditions.
	
N.A.
Leadership Indicators
1.	
Does the entity extend any life insurance or any compensatory package in the event of death of
	
(A) 	 Employees (Y/N) Yes
	
(B) 	 Workers (Y/N)  Yes
2.	
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by 
the value chain partners.
	
The Company periodically inspect the records of the value chain partners to ensure that the statutory Compliance are duly 
complied. In case of any non-compliance or delayed compliance, the Company ensures that the statutory compliances are 
complied at the earliest by the value chain partner and releases the payments upon submission of documentary evidence.
3.	
Provide the number of employees/ workers having suffered high consequence work related injury/ ill-health/ 
fatalities (as reported in Q11 of Essential Indicators above), who have been are rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment:
Total no. of affected employees/workers
No. of employees/workers that are 
rehabilitated and placed in suitable 
employment or whose family members 
have been placed in suitable employment
FY 2022-23
FY 2021-22
FY 2022-23
FY 2021-22
Employees
0
0
0
0
Workers
0
0
0
0
4.	
Does the entity provide transition assistance programs to facilitate continued employability and the management of 
career endings resulting from retirement or termination of employment? (Yes/ No)
	
Yes
5.	
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such partners)  
that were assessed
Health and safety practices
100%
Working Conditions
100%
6.	
Provide details of any corrective actions taken or underway to address significant risks/concerns arising from 
assessments of health and safety practices and working conditions of value chain partners.
	
No pending action arising from assessments of health and safety practices and working conditions of value chain partners.
	
All safety related accidents are being investigated and learnings from investigation reports are shared across organisation for 
deployment of corrective actions to stop recurrence of such incidents. Effectiveness of Corrective actions deployment being 
checked during safety Audits/ internal audits Loss control tours.
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
13
PRINCIPLE 4: Businesses should respect the interests of and be responsive to all its stakeholders
Essential Indicators
1.	
Describe the processes for identifying key stakeholder groups of the entity.
2.	
List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder 
group.
Stakeholder 
Group
Whether identified 
as Vulnerable & 
Marginalized Group 
(Yes/No)
Channels of communication (E-mail, SMS, 
Newspaper, Pamphlets, Advertisement, 
Community Meetings, Notice Board, Website), 
Other
Frequency of engagement 
(Annually/ Half yearly/ 
Quarterly/ others – please 
specify)
Purpose and scope of 
engagement including key topics 
and concerns raised during such 
engagement
Shareholders
No
Annual General Meetings, other shareholder
meetings, e-mail communications, Stock 
Exchange (SE) intimations, investor/ analysts 
meet/ conference calls, Annual
Reports, quarterly results, media releases, 
Company’s website
Ongoing
Financial results, dividends, 
financial stability, induction 
of board members, changes 
in shareholdings, growth 
prospects
Employees 
and 
workers
No
Regular E-mails, Website, Tool Box Talk, 
Notice Boards, Town Hall
Ongoing
Performance analysis
and career path setting, 
Training and awareness, 
health, safety and engagement 
initiatives
Value Chain 
Partners
No
Vendor Meet
Ongoing
Quality, timely delivery fair and 
competitive pricings. Product 
quality and availability, 
responsiveness to needs,
Government
No
Meetings with local
administration/ state government
authorities through seminars on need basis
Ongoing
Statutory compliance,
transparency in disclosures, 
tax revenues, sound corporate 
governance mechanisms
Communities Yes
Community visits and projects, partnership 
with local charities,
CSR initiatives
Ongoing
Assess local community’s 
needs, strengthen livelihood
opportunities, education, 
health care and humanitarian 
relief.
Leadership Indicators
1.	
Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social 
topics or if consultation is delegated, how is feedback from such consultations provided to the Board.
	
The Company’s management regularly interacts with its key stakeholders i.e. investors, customers, suppliers, employees, etc. The 
Company also has Corporate Social Responsibility Committee and Audit Committee which updates the progress on the actions 
taken to the Board and takes inputs and guidance from the Board on a quarterly basis.
2.	
Whether stakeholder consultation is used to support the identification and management of environmental, and social 
topics (Yes/No). If so, provide details of instances as to how the inputs received from stakeholders on these topics 
were incorporated into policies and activities of the entity.
	
Yes, the Company engages with its stakeholders in terms of identifying and prioritizing the issues pertaining to economic, 
environmental and social topics.
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
14
PRINCIPLE 5: Businesses should respect and promote human rights
Essential Indicators
1.	
Employees and workers who have been provided training on human rights issues and policy(ies) of the entity, in the 
following format:
Category
FY 2022-23
FY 2021-22
Total (A)
No. of employees/ 
workers covered (B)
% (B / A)
Total (C)
No. of employees/ 
workers covered (D)
% (D / C)
Employees
Permanent
2569
1723
67.07%
2569
1723
67.07%
Total Employees
2569
1723
67.07%
2569
1723
67.07%
Workers
Permanent
0
0
0
0
0
0
Other than permanent
0
0
0
0
0
0
Total Workers
0
0
0
0
0
0
2.	
Details of minimum wages paid to employees and workers, in the following format:
Category
FY 2022-23
FY 2021-22
Total (A)
Equal to Minimum Wage
More than Minimum Wage
Total (D)
Equal to Minimum Wage
More than Minimum Wage
No. (B)
% (B / A)
No. (C)
% (C / A)
No. (E)
% (E / D)
No. (F)
% (F / D)
Employees
Permanent
Male
2494
-
-
2494
100%
2278
Female
75
-
-
75
100%
62
Other than 
Permanent
Male
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
Workers
Permanent
Male
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
Other than 
Permanent
Male
0
0
0
0
0
0
0
0
0
0
Female
0
0
0
0
0
0
0
0
0
0
3.	
Details of remuneration/ salary/ wages, in the following format:
Male
Female
Number
Median remuneration/ 
salary/ wages of 
respective category
Number
Median remuneration/ 
salary/ wages of 
respective category
Board of Directors (BoD)
4
 2,92,04,295
0
 -
Key Managerial Personnel (excluding MD and ED)
2
98,87,558
0
 -
Employees other than BoD and KMP
1042
 5,62,200
72
 4,08,000
Workers
1435
 2,56,800
2
 3,17,940
4.	
Do you have a focal point (Individual/Committee) responsible for addressing human rights impacts or issues caused 
or contributed to by the business? (Yes/No)
	
Yes
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
15
5.	
Describe the internal mechanisms in place to redress grievances related to human rights issues.
	
Grievance Redressal Committee, POSH Policy Implementation, SA 8000:2014 certification
6.	
Number of Complaints on the following made by employees and workers:
FY 2022-23
FY 2021-22
Filed during 
the year
Pending resolution 
at the end of year
Remarks
Filed during 
the year
Pending resolution 
at the end of year
Remarks
Sexual Harassment
2
0
1
0
Discrimination at workplace
0
0
0
0
Child Labor
0
0
0
0
Forced Labor/Involuntary Labor
0
0
0
0
Wages
0
0
0
0
Other human rights related issues
0
0
0
0
7.	
Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.
	
Grievance Redressal Committee, Works committee acts as per defined Mechanism, Certified Standing Orders
8.	
Do human rights requirements form part of your business agreements and contracts? (Yes/No)
	
Yes
9.	
Assessments for the year:
% of your plants and offices that were assessed  
(by entity or statutory authorities or third parties)
Child labour
100%
Forced/involuntary labour
100%
Sexual harassment
100 %
Discrimination at workplace
100%
Wages
100%
Others – please specify
100%
10.	 Provide details of any corrective actions taken or underway to address significant risks/concerns arising from the 
assessments at Question 9 above.
	
SA 8000:2014 Social Accountability Standard requirements are implemented.
Leadership Indicators
1.	
Details of a business process being modified/ introduced as a result of addressing human rights grievances/ 
complaints.
	
No such grievances/complaints on Human Rights violations.
2.	
Details of the scope and coverage of any Human rights due-diligence conducted. N/A
3.	
Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of 
Persons with Disabilities Act, 2016?
	
Yes
4.	
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such partners)  
that were assessed
Sexual Harassment
100%
Discrimination at workplace
100%
Child Labor
100%
Forced Labor/Involuntary Labor
100%
Wages
100%
Others – please specify
100%
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
16
5.	
Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the 
assessments at Question 4 above.
	
No Significant Risk. All requirements of SA 8000:2014 being complied.
PRINCIPLE 6: Businesses should respect and make efforts to protect and restore the environment
Essential Indicators
1.	
Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:
Parameter
FY 2022-23
FY 2021-22
Total electricity consumption (A)
170
222.80
Total fuel consumption (B)
1594
2077
Energy consumption through other sources (C)
16.6
6.2
Total energy consumption (A+B+C)
1780.60
2306
Energy intensity per rupee of turnover
(Total energy consumption/ turnover in rupees)
109239
141472
Energy intensity (optional) – the relevant metric may be selected by the entity
2184
1630
	
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
	
Yes, ISO 50001 :2018 Energy management system implemented and site was audited by BSI
2.	
Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, Achieve 
and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under the PAT scheme 
have been achieved. In case targets have not been achieved, provide the remedial action taken, if any.
	
No
3.	
Provide details of the following disclosures related to water, in the following format:
Parameter
FY 2022-23
FY 2021-22
Water withdrawal by source (in kilolitres)
(i) 	 Surface water
214477
214549
(ii) 	 Groundwater
13916
15845
(iii)	 Third party water
0
0
(iv) 	Seawater/desalinated water
0
0
(v)	 Others
0
0
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
228393
230394
Total volume of water consumption (in kilolitres)
228393
230394
Water intensity per rupee of turnover (Water consumed / turnover)
0.00001
0.00001
	
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
	
Yes, British Standard Institution (BSI)
4.	
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation.
	
Yes, 1) Waste Effluent from all the plants comes to the ZLD facility established within the industry and the treated water is resued in 
Cooling towers. 2) ZLD SOP is in place to avoid any deviations in the process for smooth functioning. 3) Separate Lab is established 
for regular testing of the incoming streams.
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
17
5.	
Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:
Parameter
Please specify unit
FY 2022-23
FY 2021-22
NOx
μg/m3
118
53
SOx
μg/m3
39
80
Particulate matter (PM)
miligrams/cubic meter
94.30
71.25
Persistent organic pollutants (POP)
N.A.
0
0
Volatile organic compounds (VOC)
ppm
350
360
Hazardous air pollutants (HAP)
N.A.
N.A.
N.A.
Others– please specify
N.A.
N.A.
N.A.
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
	
YES, Precitech Laboratories, State Pollution Control Board, Envirotech Laboratories
6.	
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following format:
Parameter
Unit
FY 2022-23
FY 2021-22
Total Scope 1 emissions (Break-up of the GHG into CO2, CH4, N2O, 
HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of CO2
Equivalent
23786
24928
Total Scope 2 emissions (Break-up of the GHG into CO2, CH4, N2O, 
HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of CO2
equivalent
6134
1171
Total Scope 1 and Scope 2 emissions per rupee of turnover
0.000013
0.000011
	
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
	
Yes, Inline GRI guidelines and ISO 14064-1 GHG emission verification audit
7.	
Does the entity have any project related to reducing Green House Gas emission? If Yes, then provide details.
	
Yes, Initiatives by Cogen:
	
1.	
Steam saving by replacement of 12.1 MW Turbine with 12.4 MW turbine.
	
2.	
Steam saving by heating DM water from 45 degree Celsius to 85 degree Celsius before feeding into the boiler using the steam.
	
3.	
Replacement of Diesel Fork lift by EV fork lift
	
4.	
Solar Panel installation to bring down scope 2 of GHG emissions
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
18
8.	
Provide details related to waste management by the entity, in the following format:
Parameter
FY 2022-23
FY 2021-22
Total Waste generated (in metric tonnes)
Plastic waste (A)
24.359
18.050
E-waste (B)
0.520
0.430
Bio-medical waste (C)
0.0325
0.0309
Construction and demolition waste (D)
0
0
Battery waste (E)
2.08
1.02
Radioactive waste (F)
0
0
Other Hazardous waste. Please specify, if any. (G)
1665.183
13.73
Other Non-hazardous waste generated (H). Please specify, if any.
(Break-up by composition i.e. by materials relevant to the sector)
0
0
Total (A+B + C + D + E + F + G + H)
1692.175
33.2609
For each category of waste generated, total waste recovered through recycling, re-using or
other recovery operations (in metric tonnes)
Category of waste
(i) 	 Recycled
36.366
18.25
(ii) 	 Re-used
N.A.
N.A.
(iii) 	Other recovery operations
N.A.
N.A.
Total
36.366
18.25
For each category of waste generated, total waste disposed by nature of disposal method  
(in metric tonnes)
Category of waste
(i) 	 Incineration
179.666
13.93
(ii) 	 Landfilling
1473.510
NIL
(iii) 	Other disposal operations
 N.A.
 N.A.
Total
1653.176
13.93
	
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
	
Yes, ISO 14001 :2015 Environment management system implementation and was audited by BSI
9.	
Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by 
your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices 
adopted to manage such wastes.
	
1.	
Different dustbins are defined in every plant, office, OHC, Canteen for collection of waste depending on the type and 
segregating from the source itself.
	
2.	
Hazard Waste collection area is defined within the industry for storage.
	
3.	
Awareness campaign are been conducted in the premises for sustainable life and workplace management to reduce 
the waste.
	
4.	
Condensate water is collected and reused in Cooling towers.
	
5.	
Effluent treatment and reused in Cooling towers
10.	 If the entity has operations/ offices in/ around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where 
environmental approvals/clearances are required, please specify details in the following format:
	
No
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
19
Sr.
No.
Location	of  
operations/offices
Type of  
operations
Whether the conditions of environmental approval/clearance are being complied with? (Y/N) If 
no, the reasons thereof and corrective action taken, if any.
No
11.	 Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the 
current financial year:
Name and brief  
details of project
EIA
Notification No.
Date
Whether conducted by independent 
external agency (Yes /No)
Results communicated in 
public domain (Yes/No)
Relevant  
Web-link
N.A.
N.A.
N.A.
N.A.
N.A.
N.A.
12.	 Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India; such as the Water 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act 
and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:
	
Yes
Sr.  
No.
Specify the law/ regulation/ 
guidelines which was not 
complied with
Provide details of the 
non-compliance
Any fines/ penalties/ action taken by 
regulatory agencies such as pollution 
control boards or by courts
Corrective action taken,  
if any
N.A. N.A.
N.A.
N.A.
N.A.
Leadership Indicators
1.	
Provide break-up of the total energy consumed (in Joules or multiples) from renewable and non-renewable sources, 
in the following format:
Parameter
FY 2022-23
FY 2021-22
From renewable sources
Total electricity consumption (A)
116
199
Total fuel consumption (B)
1088
1851
Energy consumption through other sources (C)
5
2
Total energy consumed from renewable sources (A+B+C)
1209
2052
From non-renewable sources
Total electricity consumption (D)
54
23.8
Total fuel consumption (E)
506
226
Energy consumption through other sources (F)
11.6
4.2
Total energy consumed from non-renewable sources (D+E+F)
571.6
254
	
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
	
No
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
20
2.	
Provide the following details related to water discharged:
Parameter
FY 2022-23
FY 2021-22
Water discharge by destination and level of treatment (in kilolitres)
(i)	 To Surface water
0
0
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(ii) 	 To Groundwater
0
0
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(iii)	 To Seawater
0
0
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(iv)	 Sent to third-parties
0
0
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(v)	 Others
0
0
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
Total water discharged (in kilolitres)
0
0
	
Note: Indicate if any independent assessment/ evaluation/assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
3.	
Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):
	
For each facility/plant located in areas of water stress, provide the following information:
	
(i)	
Name of the area
	
(ii)	
Nature of operations
	
(iii)	 Water withdrawal, consumption and discharge in the following format:
Parameter
FY 2022-23
FY 2021-22
Water withdrawal by source (in kilolitres)
(i)	 Surface water
0
0
(ii)	 Groundwater
0
0
(iii)	 Third party water
0
0
(iv)	 Seawater/desalinated water
0
0
(v)	 Others
0
0
Total volume of water withdrawal (in kilolitres)
0
0
Total volume of water consumption (in kilolitres)
0
0
Water intensity per rupee of turnover (Water consumed / turnover)
0
0
Water intensity (optional) – the relevant metric may be selected by the entity
0
0
Water discharge by destination and level of treatment (in kilolitres)
(i)	 Into Surface water
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(ii)	 Into Groundwater
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(iii)	 Into Seawater
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(iv)	 Sent to third-parties
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
(v)	 Others
	
-	
No treatment
0
0
	
-	
With treatment – please specify level of treatment
0
0
Total water discharged (in kilolitres)
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
21
	
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
4.	
Please provide details of total Scope 3 emissions & its intensity, in the following format:
Parameter
Unit
FY 2022-23
FY 2021-22
Total Scope 3 emissions (Break-up of the GHG into CO2, CH4, N2O, HFCs,  
PFCs, SF6, NF3, if available)
Metric tonnes of CO2
equivalent
14419
779
Total Scope 3 emissions per rupee of turnover
0.000000065
0.000000003
Note: Indicate if any independent assessment/ evaluation/ assurance has been carried out by an external agency? (Y/N) If yes, 
name of the external agency.
5.	
With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide 
details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and 
remediation activities.
	
N.A. 
6.	
If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource 
efficiency, or reduce impact due to emissions/ effluent discharge/ waste generated, please provide details of the 
same as well as outcome of such initiatives, as per the following format:
Sr.  
No.
Initiative undertaken
Details of the initiative (Web-link, if any, may be provided along-with 
summary)
Outcome of the initiative
1
Steam saving Activity by 
Replacement of 13MW 
turbine.
Energy saving by replacement of Old 12.1 MW Turbine with new 
designed efficient 12.4 MW Turbine with same input parameters of 
steam.
Same is Published in GHG Report available on IOLCP website.
 Scope -1 Emission Reduction 
MTCO2e
 4869.738
2
Steam saving Activity by 
Replacement of 4MW 
turbine.
Energy saving by replacement of Old 4MW Turbine with new designed 
efficient 4.225MW Turbine with same input parameters of steam.
Same is Published in GHG Report available on IOLCP website.
Scope -1 Emission Reduction 
MTCO2e 
4271.98125
7.	
Does the entity have a business continuity and disaster management plan? Give details in 100 words/web-link.
	
IOL Chemicals & Pharmaceuticals ltd. is a fully backward integrated, Indian pharmaceutical company with a strong thrust on 
exports. We are the largest manufacture of different APls and different Specialty Chemicals which we produce right from the basic 
stage. APls/Chemicals are produced at world-class manufacturing facilities . These facilities have been approved by leading drug 
regulatory authorities - US FDA. Russia. WHO Geneva. HPFB Canada, KFDA Korea, EDOM.
	
With operations in over 80 countries across the globe, exports and domestic business account for approximate equal contribution 
of the Company’s income.
	
Continuity of any business with all interested parties concern & targeted growth considering the risk involve is an essential part 
of the any business organisation. Business Continuity is generally ensured by alternate arrangement of raw material, services & 
utilities required for smooth operations. Business critical functions have been analyzed for any failure and backup arrangement to 
uninterrupted supply of goods to the customers. All identified critical functions have been assessed for risk & its criticality to the 
business to set the priority for the next action to be taken to reduce the impact.
	
A documented guiding document has been established by IOLCP which can be referred in case of major fire ,data loss, flooding, 
raw material supply interruption which may occur during performing any business operation.
8.	
Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What 
mitigation or adaptation measures have been taken by the entity in this regard.
	
N.A.
9.	
Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.
	
100% key Raw material suppliers on the basis on internal Assessment on ESG
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
22
PRINCIPLE 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is 
responsible and transparent
Essential Indicators
1.	
a)	
Number of affiliations with trade and industry chambers/associations.
	
	
Six
	
b)	
List the top 10 trade and industry chambers/ associations (determined based on the total members of such 
body) the entity is a member of/ affiliated to.
Sr. 
No.
Name of the trade and industry chambers/associations
Reach of trade and industry chambers/associations (State/National)
1.
Phd chamber of commerce and industry
National - India
2.
Apex chamber of commerce and Industry
National - India
3.
Indian Chemical Council
National - India
4.
Confederation of Indian Industry
National - India
5.
Pharmexcil
National - India
6.
Chemexcil
National - India
2.	
Provide details of corrective action taken or underway on any issues related to anticompetitive conduct by the entity, 
based on adverse orders from regulatory authorities.
Name of authority
Brief of the case
Corrective action taken
NIL
NIL
NIL
Leadership Indicators
1.	
Details of public policy positions advocated by the entity: No
Sr.  
No.
Public policy  
advocated
Method resorted for  
such advocacy
Whether information 
available in public domain? 
(Yes/No)
Frequency of Review by Board 
(Annually/ Half yearly/ Quarterly/ 
Others – please specify)
Web-link,  
if available
NO
PRINCIPLE 8: Businesses should promote inclusive growth and equitable development
Essential Indicators
1.	
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the 
current financial year.
Name and brief 
details of project
SIA Notification No.
Date of notification
Whether conducted by 
independent external 
agency (Yes / No)
Results communicated in 
public domain (Yes / No)
Relevant Web-link
N.A.
N.A.
N.A.
N.A.
N.A.
N.A.
2.	
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by 
your entity, in the following format:
Sr.  
No.
Name of Project for which 
R&R is ongoing
State
District
No. of Project Affected 
Families (PAFs)
% of PAFs covered 
by R&R
Amounts paid to PAFs in 
the FY (In INR)
N.A. N.A.
N.A.
N.A.
N.A.
N.A.
N.A.
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
23
3.	
Describe the mechanisms to receive and redress grievances of the community.
	
The Company works closely with the community for carrying out the Corporate Social Responsibility initiatives. Within the 
area of work, the employees of the Company work with the communities to understand the impact of the projects on the 
intended beneficiaries. These interactions provide the people with various opportunities to identify and address the community 
issues/concerns.
4.	
Percentage of input material (inputs to total inputs by value) sourced from suppliers:
FY 2022-23
FY 2021-22
Directly sourced from MSMEs/small producers
11.01%
11.46%
Sourced directly from within the district and neighbouring districts
39.94%
48.75%
Leadership Indicators
1.	
Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact Assessments 
(Reference: Question 1 of Essential Indicators above):
Details of negative social impact identified
Corrective action taken
Not Applicable
2.	
Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as 
identified by government bodies:
Sr.  
No
State
Aspirational District
Amount spent (In INR)
Not Applicable
3.	
(a)	
Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalized/vulnerable groups? (Yes/No)
	
	
No. However, We have as a standard policy in general terms of condition of PO that the Company promotes diversification 
of vendors and does not discriminate the vendor on the basis of their name, religion, a small, minority own, women owned, 
disadvantage/disabled, veteran owned and LGBTQA business enterprises.
	
(b)	 From which marginalized/vulnerable groups do you procure? N/a
	
(c)	
What percentage of total procurement (by value) does it constitute? N/a
4.	
Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity (in the 
current financial year), based on traditional knowledge:
	
Not Applicable
5.	
Details of corrective actions taken or underway, based on any adverse order in intellectual property related disputes 
wherein usage of traditional knowledge is involved.
	
Not Applicable
IOL Chemicals and Pharmaceuticals Limited  |  Annual Report 2022-23
24
6.	
Details of beneficiaries of CSR Projects:
Sr. 
No.
CSR Project
No. of persons benefitted from  
CSR Projects
% of beneficiaries from vulnerable 
and marginalized groupsh
1
Preventive health care & sanitation, Eradicating hunger
The CSR projects of the Company are being carried in the nearby area of 
the Company’s to benefit most of the persons from marginalized group
2
Community Development
3
Environmental sustainability and Disaster Relief
4
Benefit of armed force veterans, war widows and 
their dependents
5
Promoting education among children
6
Animal welfare
Animals in and around the activity area
PRINCIPLE 9: Businesses should engage with and provide value to their consumers in a responsible manner
Essential Indicators
1.	
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
	
We have a designated team for receiving and resolving any grievances and the respective departments have been devised along 
with an escalation matrix for unresolved grievances. The complaints, if any, are settled within a stipulated time frame on a priority 
basis by identifying root cause and taking corrective actions accordingly to the satisfaction of customer.
2.	
Turnover of products and/ services as a percentage of turnover from all products/ service that carry information 
about:
As a percentage to total turnover
Environmental and social parameters relevant to the product
100%
Safe and responsible usage
100%
Recycling and/or safe disposal
100%
3.	
Number of consumer complaints in respect of the following:
FY 2022-23
Remarks
FY 2021-22
Remarks
Received during 
the year
Pending 
resolution at end 
of year
Received during 
the year
Pending 
resolution at end 
of year
Data privacy
0
0
N.A.
0
0
N.A.
Advertising
0
0
N.A.
0
0
N.A.
Cyber-security
0
0
N.A.
0
0
N.A.
Delivery of essential services
0
0
N.A.
0
0
N.A.
Restrictive Trade Practices
0
0
N.A.
0
0
N.A.
Unfair Trade Practices
0
0
N.A.
0
0
N.A.
Other
41
34
N.A.
39
39
N.A.
4.	
Details of instances of product recalls on account of safety issues:
Number
Reasons for recall
Reasons for recall
0
N.A.
Forced recalls
0
N.A.
Business Responsibility and Sustainability Report (Contd.)
Financial Statements
Statutory Reports
Corporate Overview
25
5.	
Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No) If available, 
provide a web-link of the policy.
	
No. However, we are adhering the best practices to overcome the cyber threats.
6.	
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of 
essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; 
penalty/ action taken by regulatory authorities on safety of products/ services.
	
There have been no issues related to advertising and delivery of essential services, cyber security, and data privacy of customers. 
Also, there was no action by any regulatory authority, and no issues on safety of the product.
	
However, regular reviews are conducted to improve cyber security, the measures to safeguard data privacy are taken and needs 
are evaluated with reference to best practices and effective measures are adopted in the company.
Leadership Indicators
1.	
Channels/platforms where information on products and services of the entity can be accessed (provide web-link, if 
available).
	
Information relating to all products of the Company are available on the website at https://www.iolcp.com/business/business-
overview
2.	
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
	
IOLCP provides Material Safety Data Sheet (MSDS) while dispatching products to its customer which contains information 
pertaining to safe handling and product storage. Risks/hazards related to product and steps to mitigate risks are incorporated 
in MSDS.
3.	
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
	
The Company provide information to its customers through e-mails and phone calls.
4.	
Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/
No/Not Applicable) If yes, provide details in brief.
	
Yes, our product labels are in compliance with prevailing regulatory guidelines and mandatory information is displayed on 
product labels. As per customer requirement additional information is also provided, if any, like TREM card required during 
material transportation.
	
Did your entity carry out any survey with regard to consumer satisfaction relating to the major products/services of 
the entity, significant locations of operation of the entity or the entity as a whole? (Yes/No)
	
Yes
5.	
Provide the following information relating to data breaches:
	
a)	
Number of instances of data breaches along-with impact
	
	
0
	
b)	
Percentage of data breaches involving personally identifiable information of customers
	
	
0%
